Active or latent infection requiring resolution / prophylaxis before initiating ICI (anti...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-MELANOMA-INFECTION-SCREENING |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MELANOMA |
| Sources | SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Red Flag Origin
| Definition | Active or latent infection requiring resolution / prophylaxis before initiating ICI (anti-PD1 ± anti-CTLA4) or BRAFi+MEKi in advanced melanoma: HBsAg+ or anti-HBc+ (HBV reactivation risk on ICI; baseline HBV DNA + antiviral prophylaxis if reactivation history), HCV-RNA+ (DAA coordination; ICI generally safe with controlled HCV), HIV-positive (ICI safe with virologic suppression on ART; CHECKMATE HIV cohorts confirm efficacy), active TB, or active uncontrolled infection. |
|---|---|
| Clinical direction | hold |
| Category | infection-screening |
Trigger Logic
{
"any_of": [
{
"finding": "hbsag",
"value": "positive"
},
{
"finding": "anti_hbc_total",
"value": "positive"
},
{
"finding": "hcv_rna",
"value": "positive"
},
{
"finding": "hiv_status",
"value": "positive"
},
{
"finding": "active_tb",
"value": true
},
{
"finding": "active_uncontrolled_infection",
"value": true
}
],
"type": "composite"
}
Notes
ICI + chronic HBV: HBsAg+ → entecavir or tenofovir prophylaxis from before first ICI dose through ≥6 months post-last-dose; monitor HBV DNA q3mo. Anti-HBc+ alone (resolved HBV): monitor HBV DNA + ALT q3mo, prophylaxis only if reactivation. HIV+ with CD4 >100 + viral load suppressed on ART: ICI active and tolerable (CHECKMATE-358 HIV cohort). Active TB: complete intensive-phase anti-TB before initiating ICI to avoid masking IRIS / TB worsening on immune reconstitution. Direction "hold" surfaces a workup-prerequisite annotation rather than switching indication.
Used By
No reverse references found in the YAML corpus.